CHOLESTASIS TREATMENT MARKET ANALYSIS
Key Developments
Major players in the market are focused on conducting clinical trials to assess their novel therapies for the treatment of cholestasis. For instance, in July 2019, Genkyotex, a biopharmaceutical company, announced positive post-hoc analysis of phase 2 trial that assessed the use of Setanaxib, a NOX-1/4 enzyme inhibitor, for the treatment of cholestatic liver disease.
Research and development related to cholestasis is expected to boost the market growth. For instance, a study presented by the Icahn School of Medicine at Mount Sinai, New York at Digestive Disease Week 2019 in San Diego identified a link between intrahepatic cholestasis of pregnancy and nonalcoholic fatty liver disease.
Need a Custom Report?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now
Credibility and Certifications
9001:2015
27001:2022
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
U.S.: 
U.K. : 
India : 
